Comparative Analysis of Metabolic Syndrome Components in Individuals with Normal and Elevated Inflammatory Activity
DOI:
https://doi.org/10.63682/jns.v14i10S.2870Keywords:
Metabolic Syndrome, Systemic Inflammation, Cardiovascular Risk, Bone Health, Insulin ResistanceAbstract
Background: Metabolic Syndrome (MS) comprises interrelated metabolic abnormalities, including central obesity, dyslipidemia, hypertension, and hyperglycemia, linked to increased cardiovascular and type 2 diabetes mellitus risk. Chronic low-grade systemic inflammation exacerbates these components, contributing to their clustering. However, limited studies have explored the differential impact of inflammatory activity on MS components. This study aims to compare MS components in individuals with normal and elevated inflammatory activity, with a focus on their association with bone disorders.
Methods: A cross-sectional study was conducted on 250 patients aged 20–80 years diagnosed with bone disorders. Participants were categorized based on inflammatory markers, particularly C-reactive protein (CRP). Data on anthropometric parameters, blood pressure, fasting blood glucose, lipid profiles, and bone turnover markers were collected. Dual-energy X-ray absorptiometry (DXA) assessed bone mineral density (BMD). Statistical analyses included independent t-tests and regression models to evaluate associations.
Results: Among the participants, elevated inflammatory activity was strongly correlated with metabolic abnormalities. Raised fasting blood sugar (FBS) was the most prevalent MS component in individuals with high inflammatory activity (27%), followed by central obesity (24%). Conversely, raised triglycerides (37.19%) and reduced HDL cholesterol (18.48%) were more common in individuals with normal inflammatory activity. A significant overlap was observed between MS and bone disorders, with 72.4% of patients showing both conditions. Osteoarthritis and rheumatoid arthritis were the most reported bone disorders, each affecting 52 patients.
Conclusion: The study underscores inflammation’s central role in modulating MS components and its association with bone disorders. These findings advocate for integrating inflammatory markers into MS risk stratification, fostering personalized therapeutic approaches to improve metabolic and skeletal outcomes. Future research should expand on longitudinal dynamics and therapeutic efficacy in diverse populations.
Downloads
Metrics
References
Alberti, K. G., Zimmet, P., & Shaw, J. (2006). Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetic Medicine, 23(5), 469-480. DOI: 10.1111/j.1464-5491.2006.01858.x
Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature, 444(7121), 860-867. DOI: 10.1038/nature05485
Grundy, S. M. (2016). Metabolic syndrome update. Trends in Cardiovascular Medicine, 26(4), 364-373. DOI: 10.1016/j.tcm.2015.10.004
Esser, N., Paquot, N., & Scheen, A. J. (2014). Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Diabetes & Metabolism, 41(6), 397-405. DOI: 10.1016/j.diabet.2014.12.006
Ridker, P. M. (2003). C-reactive protein: A simple test to help predict risk of heart attack and stroke. Circulation, 108(12), e81-e85. DOI: 10.1161/01.CIR.0000093381.57779.67
Wellen, K. E., & Hotamisligil, G. S. (2005). Inflammation, stress, and diabetes. The Journal of Clinical Investigation, 115(5), 1111-1119. DOI: 10.1172/JCI25102
Compston, J. E., McClung, M. R., & Leslie, W. D. (2019). Osteoporosis. The Lancet, 393(10169), 364-376. DOI: 10.1016/S0140-6736(18)32112-3
Raisz, L. G. (2005). Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. The Journal of Clinical Investigation, 115(12), 3318-3325. DOI: 10.1172/JCI27071
Nguyen, T. V., Center, J. R., & Eisman, J. A. (2014). Osteoporosis: Genetics and mechanisms of fracture prevention. The Lancet Diabetes & Endocrinology, 2(1), 34-42. DOI: 10.1016/S2213-8587(13)70195-8
Ganesan, K., Teklehaimanot, T. D., Asokan, S., & Anitha, M. (2019). Relationship between metabolic syndrome and bone health. Journal of Clinical Medicine Research, 11(6), 351-358. DOI: 10.14740/jocmr3835
Grundy, S. M., Cleeman, J. I., Daniels, S. R., et al. (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112(17), 2735-2752. DOI: 10.1161/CIRCULATIONAHA.105.169404
Bartoli, E., Fra, G. P., & Carnevale Schianca, G. P. (2011). The oral glucose tolerance test (OGTT) revisited. European Journal of Internal Medicine, 22(1), 8-12. DOI: 10.1016/j.ejim.2010.07.008
Pradhan, A. D. (2007). Obesity, metabolic syndrome, and type 2 diabetes: Inflammatory basis of glucose metabolic disorders. Nutrition Reviews, 65(Suppl 3), S152-S156. DOI: 10.1111/j.1753-4887.2007.tb00364.x
Matsuzawa, Y. (2006). The metabolic syndrome and adipocytokines. FEBS Letters, 580(12), 2917-2921. DOI: 10.1016/j.febslet.2006.04.028
Ross, R., & Bradshaw, A. J. (2009). The future of obesity reduction: Beyond weight loss. Nature Reviews Endocrinology, 5(6), 319-325. DOI: 10.1038/nrendo.2009.78
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
